Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer
S Dees, R Ganesan, S Singh, IS Grewal - Molecular cancer therapeutics, 2020 - AACR
Triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype that lacks
estrogen receptor, progesterone receptor, and HER2 expression, does not respond to …
estrogen receptor, progesterone receptor, and HER2 expression, does not respond to …
Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment
Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern
approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah® and …
approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah® and …
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy
CAR-T cell therapy, as a novel immunotherapy approach, has indicated successful results in
the treatment of hematological malignancies; however, distinct results have been achieved …
the treatment of hematological malignancies; however, distinct results have been achieved …
Immune therapy for liver cancers
M Hilmi, A Vienot, B Rousseau, C Neuzillet - Cancers, 2019 - mdpi.com
Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor prognosis
with 5-year overall survival rates around 15%, all stages taken together. These primary liver …
with 5-year overall survival rates around 15%, all stages taken together. These primary liver …
[HTML][HTML] Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival
B Cucchiaro, NA Davies, CE Weekes, M O'Reilly… - Clinical Nutrition …, 2024 - Elsevier
Summary Background & aims Chimeric Antigen Receptor (CAR) T-cell therapy has emerged
as a revolutionary treatment for patients with refractory or relapsed B-cell malignancies …
as a revolutionary treatment for patients with refractory or relapsed B-cell malignancies …
Aging and immunotherapies: New horizons for the golden ages
JAG Hamilton, CJ Henry - Aging and cancer, 2020 - Wiley Online Library
The life expectancy of the world's elderly population (65 and older) continues to reach new
milestones with older individuals currently comprising greater than 8.5%(617 million) of the …
milestones with older individuals currently comprising greater than 8.5%(617 million) of the …
CAR T cells: living HIV drugs
H Namdari, F Rezaei, M Teymoori‐Rad… - Reviews in Medical …, 2020 - Wiley Online Library
Human immunodeficiency virus type 1 (HIV‐1), the virus that causes AIDS (acquired
immunodeficiency syndrome), is a major global public health issue. Although the advent of …
immunodeficiency syndrome), is a major global public health issue. Although the advent of …
Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy
B Cucchiaro, CE Weekes - Clinical Nutrition ESPEN, 2021 - Elsevier
Summary Background & aims Chimeric Antigen Receptor (CAR) T cell therapy is a novel
adoptive immunotherapy that is revolutionising the treatment of haematological …
adoptive immunotherapy that is revolutionising the treatment of haematological …
Cancer immunotherapy in adult patients with HIV
S Abu Khalaf, D Dandachi… - Journal of …, 2022 - journals.sagepub.com
The availability of antiretroviral therapy (ART) has increased the life expectancy of people
with HIV (PWH) and reduced the incidence of AIDS-associated malignancies, yet PWH have …
with HIV (PWH) and reduced the incidence of AIDS-associated malignancies, yet PWH have …
[HTML][HTML] a primer on chimera associated Receptor T-cells
S Muthineni, K Zink, S Kambhampati - Missouri Medicine, 2021 - ncbi.nlm.nih.gov
Cancer continues to be one of the leading causes of death. Although survival rates have
improved with current treatments for hematological malignancies, relapsed and refractory …
improved with current treatments for hematological malignancies, relapsed and refractory …